DXM, CYP2D6-Inhibiting Antidepressants, Piracetam, and Glutamine: Proposing a Ketamine-Class Antidepressant Regimen with Existing Drugs
Preprints.org – November 25, 2025
Source: OpenAlex
Summary
Rapid-acting antidepressants can elevate mood within hours by shifting glutamatergic circuits from an "NMDA-dominant" to an "AMPA-dominant" state. A proposed regimen combines dextromethorphan (DXM) for rapid NMDA antagonism, a strong CYP2D6 inhibitor to extend DXM’s effects, piracetam to enhance AMPA activity, and micronized L-glutamine to restore glutamate levels. Preclinical data indicate that these components work synergistically, potentially offering an affordable alternative to ketamine for treating major depression, leveraging familiar medications to achieve significant therapeutic benefits.
Abstract
Rapid‐acting antidepressants show that mood can lift within hours when glutamatergic circuits are pushed from an "NMDA-dominant" to an "AMPA-dominant" state. Intravenous ketamine achieves this flip but is hampered by dissociative side-effects and clinical logistics, while the oral pairing of dextromethorphan + bupropion (Auvelity®) delivers only the initial NMDA blockade and therefore yields slower, less durable benefit. We propose a fully oral, low-cost, four-component regimen designed to replicate ketamine's entire plasticity cascade: (1) dextromethorphan (DXM) supplies fast NMDA antagonism; (2) a strong CYP2D6 inhibitor (fluoxetine, paroxetine, or high-dose duloxetine) prolongs DXM exposure without relying on bupropion; (3) the AMPA positive allosteric modulator piracetam amplifies the downstream glutamate burst, driving BDNF- and mTOR-dependent synaptogenesis; and (4) micronized L-glutamine restores presynaptic glutamate pools and buffers against excitotoxicity. Preclinical evidence shows that each element—DXM's ketamine-like behavioral effects, piracetam's enhancement of AMPA currents, and glutamine's reversal of stress-induced glutamatergic depletion—synergizes along the same mechanistic axis. This strategy could democratize ketamine-level efficacy using inexpensive, readily available medications.